Research Triangle Park, North Carolina, April 19, 2023 – FUJIFILM Diosynth Biotechnologies, a world leading contract development and manufacturing organization for biologics, vaccines, and advanced therapies, today announced the acquisition of 41 acres of land adjacent to its existing state-of-the-art campus in Research Triangle Park (RTP), North Carolina. The additional 41 acres brings the total campus size to just under 119 acres in RTP giving the company room to grow for future capacity for manufacturing and development of biologics. 

The FUJIFILM Diosynth Biotechnologies RTP campus is comprised of three main buildings which include over 170,000 square feet dedicated to GMP manufacturing of biologics; 151,000 square feet of process and analytical development laboratories* and ~60,000 square feet of administration space. Currently there are over 650 employees at the RTP campus. 

Since 2014, FUJIFILM Diosynth Biotechnologies has significantly grown its footprint in RTP, most recently with the expansion of its BioProcess Innovation Center, which broke ground in April 2022. That expansion will double the site’s laboratory space and capacity to support Process Characterization programs. The expanded laboratories will be fully operational in spring 2024.

“With an established history in RTP, we’ve been able to build strong relationships with academia and the local, regional and state communities, to ensure we are building a strong foundation for the future,” said Chris Vannais, chief operating officer, FUJIFILM Diosynth Biotechnologies, RTP. “We look forward to continuing our growth in RTP, so that we are well positioned to continue providing life-impacting therapeutics.” 
——————-
* 89,000 square feet of which are part of the on-going laboratory expansion under construction.

About FUJIFILM Diosynth Biotechnologies
FUJIFILM Diosynth Biotechnologies, a subsidiary of FUJIFILM Corporation, is a world-leading contract development and manufacturing organization partner to development and manufacture of biologics, vaccines and advanced therapies. The company operates a global network with major locations in the Unites States of America, the United Kingdom and Denmark and it is building a new manufacturing site in Holly Springs, North Carolina, USA. FUJIFILM Diosynth Biotechnologies has over thirty years of experience in the development and manufacturing of recombinant proteins, vaccines, monoclonal antibodies, among other large molecules, viral products and medical countermeasures expressed in a wide array of microbial, mammalian, and host/virus systems. The company offers a comprehensive list of services from cell line development using its proprietary pAVEway™ microbial and Apollo™X cell line systems to process development, analytical development, clinical and FDA-approved commercial manufacturing. Mitsubishi Corporation is a 20% shareholder of FUJIFILM Diosynth Biotechnologies’ UK, Research Triangle Park, North Carolina, Watertown, Massachusetts and College Station, Texas sites.  For more information, go to: www.fujifilmdiosynth.com.

About FUJIFILM Holdings Corporation
FUJIFILM Holdings Corporation, Tokyo, leverages its depth of knowledge and proprietary core technologies to deliver Value from Innovation in our products and services in the business segments of healthcare, materials, business innovation, and imaging. Our relentless pursuit of innovation is focused on providing social value and enhancing the lives of people worldwide. Fujifilm is committed to responsible environmental stewardship and good corporate citizenship. For more information about Fujifilm’s Sustainable Value Plan 2030, click here. For the year ended March 31, 2022, the company had global revenues of approximately 2.5 trillion yen (21 billion $USD at an exchange rate of 122 yen/dollar). For more information, please visit: www.fujifilmholdings.com.